Illumina

Truveta is a healthcare data platform that collaborates with physicians, life science researchers, and healthcare organizations to aggregate and analyze medical records information. By compiling data from multiple healthcare systems, Truveta de-identifies and organizes this information to provide valuable medical insights. The platform initially focused on COVID-19, aiming to expedite research efforts, enhance clinician expertise, and support families in making informed healthcare decisions. Through its innovative approach, Truveta connects treatments with outcomes and various health factors, contributing to advancements in medical research and patient care.

Cache is a biotechnology company focused on developing a groundbreaking wet operating system designed for the storage, access, and computation of biomolecules at scale. By ensuring the integrity and fidelity of nucleic acids from various sources, Cache enables researchers and partners to accelerate molecular pathology research and gain insights into life sciences. This innovative approach facilitates the analysis of biomolecules, thereby unlocking new precision medicine applications and enhancing the capacity for understanding biological data. Ultimately, Cache aims to make both digital and biological data universally accessible and sustainable, eliminating the need for data deletion or disposal.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which combines computational biology, wet lab techniques, and automation. This innovative approach allows for the design, testing, and optimization of TEVs tailored for specific therapeutic applications across diverse tissue and cellular targets. In addition to its engineering capabilities, Mantra Bio has established a scalable biomanufacturing process to ensure that these novel therapeutics can be produced reproducibly and with high purity, aiming to address intractable diseases effectively.

Neurolytic Healthcare Ltd. is a medical technology company based in Oxford, United Kingdom, specializing in the design, development, and manufacture of digital and genomic-based diagnostic tools and medical devices for migraine and related neurological disorders. Founded in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnosis and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed to predict migraine events. By leveraging artificial intelligence, Neurolytic Healthcare aims to provide genomics-driven diagnostics and personalized treatment recommendations, helping patients find effective treatments while minimizing side effects and reducing the trial-and-error approach often associated with neurological care.

IDbyDNA, Inc. is a company specializing in metagenomics technologies aimed at identifying infectious diseases. Founded in 2014 and based in Salt Lake City, Utah, it has developed a platform called Explify, which enables laboratories to detect and characterize pathogens using nucleic acid-based techniques. The company offers comprehensive testing services, including respiratory and research services, catering to hospitals, reference labs, clinical research institutions, and the biopharmaceutical sector. By leveraging computational biology and artificial intelligence, IDbyDNA strives to enhance diagnostic accuracy and treatment precision for infectious diseases, addressing the growing global challenge posed by these conditions.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Enancio SAS, founded in 2017 and based in Cesson-Sévigné, France, specializes in genomic data compression software. The company's product, Lena, enhances the speed and efficiency of next-generation sequencing (NGS) analyses, significantly reducing storage costs and minimizing internal network traffic while maintaining data integrity. As a subsidiary of Illumina, Enancio’s solutions complement Illumina’s existing informatics offerings, providing users with optimal performance in genomic data management.

Bluebee is a prominent provider of high-performance genomics solutions that facilitate significant reductions in both costs and time-to-diagnosis for research and clinical laboratories. The company offers a cloud-based accelerated genomics platform designed for the fast and efficient processing of large volumes of genomic data. In light of transformative advancements in next-generation DNA sequencing technology, Bluebee addresses the challenges of handling increasing data volumes, the need for rapid data processing, and the demand for flexibility and reliability across diverse applications. By combining expertise in the field of genomics with high-performance computing and clinical-grade security, Bluebee's platform empowers healthcare institutions to explore new diagnostic methods and therapeutic options.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Edico Genome Inc. specializes in the development of bioinformatics processor chips focused on DNA analysis. The company's primary product, the DRAGEN platform, utilizes a field-programmable gate array to accelerate genome pipeline algorithms, including tasks such as BCL conversion, mapping, alignment, and variant calling. This technology enhances the efficiency of analyzing next-generation sequencing data, facilitating healthcare institutions in identifying connections between DNA sequence variations and human diseases. Founded in 2013 and headquartered in La Jolla, California, Edico Genome operates as a subsidiary of Illumina, Inc. since May 2018.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Prospect Bio is a synthetic biology company based in Brisbane, California, that focuses on developing biosensors for the detection of small molecules. These biosensors, which utilize living cells, offer a cost-effective, scalable, and field-deployable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. The company's innovative approach aims to transform testing processes across various industries, driven by the need for improved quality control and compliance with regulatory standards. Prospect Bio collaborates with a diverse range of partners, including major players in the wine industry, agriculture, and prenatal diagnostics. The company has raised $2.8 million from prominent investors, which supports its mission to enhance biosensor technology and pathway discovery through the integration of automation, computation, and synthetic biology.

Vitagene, Inc. is a health technology company that uses genomic science and advanced technology to create a DNA-based personalization platform for healthcare. It offers customized supplements directly to patients based on their individual needs for nutrition, sleep, exercise, and supplementation. The company's algorithm analyzes extensive patient data, including genetics, blood work, and lifestyle, to generate personalized supplement regimens. Vitagene also manufactures DNA health test kits and provides health and ancestry reports that outline dietary, supplement, and exercise recommendations. Additionally, the company produces at-home COVID-19 saliva test kits. Founded in 2014 and based in San Francisco, California, Vitagene aims to empower individuals with tailored health solutions through big data and machine learning.

Conexio Genomics, established in 2002 and headquartered in Fremantle, Australia, is a life sciences company specializing in genetic sequencing and mutation detection. It offers products such as Assign SBT and SBT Resolver for high-resolution sequencing and genotyping, and Assign-ATF for automated DNA sequence mutation detection. The company's solutions are used in matching patients and donors for bone marrow or cord blood transplants.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

GenoLogics, Inc. is a company that specializes in laboratory information management systems designed to enhance the diagnosis and treatment of diseases. Based in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers the BaseSpace Clarity LIMS, a solution utilized by research and clinical laboratories to efficiently track samples from receipt to result. This system aims to reduce costs, improve accuracy, and ensure rigorous quality control. The company focuses on translational medicine, genomics sequencing, systems biology research, and data management across multiple laboratories, facilitating collaborative initiatives in biomedical research. Founded in 2002, GenoLogics operates as a subsidiary of Illumina Inc., contributing to advancements in early disease detection, prevention, and treatment.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

NextBio is a privately owned software company based in Cupertino, California, that offers a web-based platform designed for life science researchers to search, discover, and share knowledge across both public and proprietary data. Co-founded in 2004 by Saeid Akhtari, Ilya Kupershmidt, and Mostafa Ronaghi, NextBio utilizes an ontology-based semantic framework that integrates diverse data types, including information on genes, tissues, diseases, and compounds. This framework allows researchers to access a comprehensive, searchable environment that correlates data from various organisms and research areas. The enterprise version of the platform is utilized by major pharmaceutical companies, enabling researchers and clinicians to upload and integrate proprietary data with publicly available information. This capability enhances the ability to identify relevant prognostic and predictive molecular signatures critical to their research. NextBio has attracted significant interest, with over 1.5 million visitors since its launch, and received recognition for its customer value enhancement in the life sciences sector.

Advanced Liquid Logic, Inc. is a company specializing in microfluidic devices for liquid handling applications, offering innovative workflow solutions for laboratories and clinics. Founded in 2004 by Dr. Michael Pollack and Dr. Vamsee Pamula, who developed the core technology during their academic research at Duke University, the company focuses on creating lab-on-a-chip devices that can be programmed to perform a variety of assay protocols, including immunoassays, polymerase chain reaction (PCR), and clinical chemistry. Under the leadership of CEO Richard West, who has a wealth of experience in business and product development, Advanced Liquid Logic aims to address unmet challenges in scientific research by providing versatile and efficient solutions in liquid handling.

Moleculo is a biotech company specializing in advanced DNA sequencing technologies aimed at enhancing genome analysis. The company has created a novel sequencing method that delivers long and accurate reads, significantly improving the efficiency and precision of various DNA sequencing applications. This innovation allows clients to explore a broader array of applications in genomics, thereby advancing research and development in the field.

Verinata Health focuses on maternal and fetal health by developing non-invasive tests for the early identification of fetal chromosomal abnormalities. Utilizing proprietary technologies, the company analyzes cell-free DNA in maternal blood to offer a safe and accurate assessment of fetal aneuploidy. This approach aims to alleviate the anxiety associated with traditional prenatal screening methods that often involve multiple steps, high false-positive rates, and invasive procedures. Verinata seeks to provide women with a straightforward solution, consisting of a single blood draw that delivers definitive results. The company is also conducting a large-scale, prospective, blinded pivotal study to validate the sensitivity and specificity of its prenatal test, with results anticipated to enhance the understanding and effectiveness of prenatal care.

BlueGnome Limited specializes in developing genetic diagnostic solutions aimed at screening for chromosomal abnormalities. Based in Fulbourn, United Kingdom, the company gained recognition for its innovative approaches to genetic testing. In 2012, BlueGnome was acquired by Illumina, a leading company in the field of genomics, further enhancing its capabilities and reach in the market for genetic diagnostics.

GenoLogics, Inc. is a company that specializes in laboratory information management systems designed to enhance the diagnosis and treatment of diseases. Based in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers the BaseSpace Clarity LIMS, a solution utilized by research and clinical laboratories to efficiently track samples from receipt to result. This system aims to reduce costs, improve accuracy, and ensure rigorous quality control. The company focuses on translational medicine, genomics sequencing, systems biology research, and data management across multiple laboratories, facilitating collaborative initiatives in biomedical research. Founded in 2002, GenoLogics operates as a subsidiary of Illumina Inc., contributing to advancements in early disease detection, prevention, and treatment.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.

Affomix is a biotechnology company specializing in the development of antibody-based products. Utilizing proprietary technology, it offers rapid and automated high-throughput selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, along with mAb microarrays and mAb libraries, for various applications in research, drug discovery, diagnostics, and therapeutics. Affomix aims to enhance the sensitivity and accuracy in measuring large numbers of proteins in biological samples, leveraging its capabilities to produce and screen antibodies against virtually all human proteins, including those that are post-translationally modified.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Pillar Biosciences Inc. is a biotechnology company that specializes in developing and manufacturing next-generation sequencing (NGS) assays and software tailored for NGS laboratories. Founded in 2014 and headquartered in Natick, Massachusetts, with an additional location in Shanghai, China, the company utilizes its patent-pending targeted sequencing technology platform to offer high sensitivity and specificity in clinical samples. Its proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology facilitates precise priming of overlapping target segments, while the PiVAT bioinformatics analysis pipeline enhances data processing. Pillar Biosciences has released beta versions of its Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel, aimed at cancer centers and clinical testing companies in the U.S. and China for validation studies. The company's innovative approach provides a fast, simple, and cost-effective method for NGS-based oncology testing, contributing to more accessible and efficient DNA analysis in the healthcare sector.